ArticleArchives of Razi Institute2025
Pinocembrin Isolated from Nigerian Propolis Prevents Elevation of Cytokines Implicated in the Aetiology of Diabetic Retinopathy in Rat Models of Diabetes Mellitus.
Article in Archives of Razi Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Propolis, a resin produced by bees-, contains the flavonoid compound pinocembrin, which shows promise for antioxidant and anti-inflammatory applications, though its therapeutic potential remains underexplored. Diabetic retinopathy, a common complication of diabetes, involves retinal inflammation and vascular damage. Previous research indicates that Nigerian propolis may have anti-hyperglycemic effects and the ability to lower glycosylated hemoglobin levels. This study evaluated the protective effects of pinocembrin, extracted from Nigerian propolis, against diabetic retinopathy in a streptozotocin-induced rat model. Diabetes was induced in male Sprague-Dawley rats through a single intraperitoneal injection of streptozotocin, resulting in sustained hyperglycemia. The diabetic rats were then administered oral pinocembrin at a dose of 50 mg/kg daily for 8 weeks. Pinocembrin effectively mitigated the elevation of inflammatory mediators, including Interleukin-1 (IL-1), Interleukin-8 (IL-8) and Tumor Necrosis Factor-alpha (TNF-α), within the retinal tissues of the treated diabetic rats. Furthermore, pinocembrin enhanced levels of the antioxidant enzymes such as Superoxide Dismutase (SOD) and Glutathione Peroxidase (GSH-Px), and also improved glycemic control and glycosylated hemoglobin levels. The results indicate that pinocembrin possesses significant therapeutic potential for preventing or mitigating diabetic retinopathy. Its capacity to regulate inflammatory processes and strengthen antioxidant defenses underscores its potential as a treatment strategy for managing this vision-threatening complication associated with diabetes mellitus.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.